Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial - The Lancet Diabetes & Endocrinology
Por um escritor misterioso
Descrição
Statins and type 2 diabetes: genetic studies on target - The Lancet
Adverse events associated with unblinded, but not with blinded
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label
Graves Disease: Practice Essentials, Pathophysiology, Epidemiology
Statin use before diabetes diagnosis and risk of microvascular
Recent advances in graves ophthalmopathy medical therapy: a
PDF) Recent advances in graves ophthalmopathy medical therapy: a
Sex-specific risk factors associated with graves' orbitopathy in
Traditional Chinese medicine in thyroid-associated orbitopathy
Full article: How can we prevent disease relapse in Graves
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label
Current and Emerging Treatment Strategies for Graves' Orbitopathy
High Serum Cholesterol Is a Novel Risk Factor for Graves
Simvastatin downregulates adipogenesis in 3T3-L1 preadipocytes and
de
por adulto (o preço varia de acordo com o tamanho do grupo)
